vTv Therapeutics
VTVT
vTv Therapeutics (VTVT) news
Recent news
VTV Therapeutics, Inc.: H.C. Wainwright cuts target price to $42 from $45
AInvest Wire · Aug 6, 2026VTV Therapeutics Inc: BTIG raises target price to $57 from $49
BTIG has raised its price target for vTv Therapeutics Inc. (NASDAQ: VTVT) to $57 from $49, while maintaining its Buy rating on the stock. The firm highlighted the company’s broader pipeline potential beyond its lead diabetes program, cadisegliatin, which is currently in Phase 3 trials for Type 1…
AInvest Wire · Jul 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.